Advancing Biotherapeutics and Vaccine Production

New bioprocessing standards
from molecule to market

Life Technologies is responding to the quest to improve the human condition by setting technology, product and safety standards for the worldwide production of biotherapeutics and vaccines.

Contact us at outlicensing@lifetech.com to learn more.




“The world's six biggest-selling drugs in 2014 will all be biotech products, underlining the importance of the sector for the global pharmaceuticals industry.”
– Forbes, June 17, 2009

New cell lines, heightened concerns about product safety, emerging biosimilars, and a vaccine industry shifting to cell culture–based production all point to a need for forward-thinking technology and product platforms. Leveraging core expertise in cell culture development, downstream purification, and rapid molecular-based contaminant testing, the Life Technologies Bioproduction group is providing workflow solutions today to a biopharmaceutical industry at the cusp of transforming traditional disease treatment.




Overcoming upstream and downstream bioprocess and analytics bottlenecks

The biotherapeutics and vaccine production solutions from Life Technologies are offered under trusted industry-leading brands: GIBCO® and Applied Biosystems®. Products and services help solve everyday problems from improving cell line titers, optimizing media formulations, and scaling cell culture production, to performing same-day critical impurity analyses and reducing purification run times.



The leader in...

Cell Culture Media Development
GIBCO® Media and Feeds and
PD-Direct® Bioprocess Services

Protein Purification - Polish Ion Exchange
POROS® Chromatography Columns

Rapid Molecular Methods for Contaminant Testing
SEQ Rapid Molecular Methods for Contaminant and Impurity Testing

GIBCO Logo Applied Biosystems Logo

To learn more about how Life Technologies is advancing biotherapeutics and vaccine production, contact BP@lifetech.com

News

  • ION TORRENT ACQUIRED

    Life Technologies, a provider of innovative life science solutions, announced a definitive agreement to acquire Ion Torrent for $375 million in cash and stock.

    Read All Close
  • New Genomic Alliance

    Life Technologies announced the creation of the Genomic Cancer Care Alliance to help people battling cancer gain access to treatment options found through analysis of their genomic information. Founding partners include Fox Chase Cancer Center, Scripps Genomic Medicine, and the Translational Genomics Research Institute (TGen).The announcement came during the Consumer Genetics Conference being held June 2-4 in Boston.

    Read All Close
  • The 2009 CSR REPORT

    Life Technologies released its 2009 Global Citizenship Report, highlighting Life Technologies' organization-wide initiatives to be a leading corporate citizen and balance environmental and social issues with its overall mission to shape biological discovery and ultimately improve life.

    Read All Close